D-1396-2019 Class III Terminated

Recalled by Bausch & Lomb — Tampa, FL

FDA drug recall D-1396-2019 was initiated by Bausch & Lomb on Jun 17, 2019 and is designated Class III. Reason for recall: Failed Stability Specifications: Out of specification for viscosity. The recall status is terminated (terminated Sep 24, 2021). Affected quantity: 170832 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 19, 2019
Initiation Date
Jun 17, 2019
Termination Date
Sep 24, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
170832 bottles

Product description

Lotemax (loteprednol etabonate ophthalmic gel 0.5%), Sterile, Rx Only, 5 g box, Bausch & Lomb, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA, NDC 24208-503-07.

Reason for recall

Failed Stability Specifications: Out of specification for viscosity.

Distribution pattern

Nationwide in the U.S.

Code information

Lot #s: 282611; 283431; 283441; 283451, Exp. 10/2019; 282971; 282981; 283611; 283621; 283631, Exp. 11/2019.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1396-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1396-2019. Report a data issue: hello@regdatalab.com.